The North America amniotic membrane market growth evaluation includes the analysis of the United States and Canada. The United States amniotic membrane market growth is attributed to the thriving biotechnology sector with regard to regenerative medicine development. Also, the US market benefits from the presence of key market players offering different products made from placental cells. In addition, numerous companies are significantly investing in the development of amniotic products. Consequently, the development of amniotic products has facilitated market demands in the regenerative medicine and advanced wound care segments. 

For instance, BioTissue Inc developed PROKERA Slim corneal bandage in August 2020, approved for use in ocular surface disease and disorders. Further, in January 2021, Organogenesis Holdings Inc announced the grant of ReNu®, a cryopreserved amniotic suspension allograft, by the US Food and Drug Administration (FDA) for managing symptoms associated with knee osteoarthritis (OA). Besides, the American Association of Tissue Banks supplements the development of amniotic membranes and enables accreditation for the distribution of the amniotic membrane or tissues. 

Furthermore, the United States amniotic membrane market prospects are defined by the vast use of amniotic membranes for eye surface disorders. Accordingly, the increasing number of ophthalmic surgeries due to the rising geriatric population is lucrative to the analyzed market’s growth. Moreover, according to the US National Library of Medicine, the application of amniotic membranes has a wide indication spectrum in treating ocular surface disorders. Amniotic membrane transplantation has been routinely incorporated as part of ocular surface reconstruction in varied ocular pathologies. 

The North America amniotic membrane market segmentation includes end-user, application, and product. The end-user segment includes specialized clinics, hospitals, ambulatory surgical centers, and research centers & laboratories.

Specialized clinics focus on the care of outpatients and a specific medical area. The providers in a specialized clinic are specifically trained in fields like dermatology, cardiology, gastroenterology, orthopedics, ophthalmology, sports medicine, neurology, etc. They are also stand-alone practices, and at the same time, often associated with a hospital group or healthcare system. They use a high-volume/cross-subsidization model to meet the huge patient demands and medical needs of the underprivileged, particularly in the areas of dentistry, kidney care, reproductive health, and eye care. The growing number of healthcare players and the increasing number of health conditions propel the growth of the segment. 

Some of the prominent firms in the North America amniotic membrane market include MiMedx Group Inc, Labtician Ophthalmics Inc, Organogenesis Inc, Smith & Nephew Plc, etc.

MiMedx is an advanced wound care and biologics company that develops and distributes placental tissue allografts. It provides products in the dental, ophthalmic, sports medicine, spine, orthopedic, surgical, burns, and wound care sectors. Its products are used in surgical applications, including plastic surgery, extremity repair, multiple orthopedic repairs and reconstructions, and vascular surgery. The company has two main distribution channels, distributors and direct-to-customers, with headquarters in Marietta, Georgia.

One of its biomaterial platform technologies, AMNIOFIX, is a dehydrated human amnion/chorion membrane allograft. It is available in wrap, fenestrated, and sheet configurations in various sizes to minimize wastage. Besides, it is derived from donated C-sections of live births in the US.